News

The Phase III SOLO-1 trial assessed Lynparza as a maintenance treatment for patients with newly-diagnosed and advanced BRCA-mutated (BRCAm) ovarian cancer, who have been in complete or partial

New investors HBM Healthcare Investments (Cayman) and Nextech Invest also took part in the mezzanine financing, said TP Therapeutics. The new capital secured by the clinical-stage precision oncology

For patients with metastatic EGFR-mutated NSCLC, targeted EGFR TKI therapies such as gefitinib, erlotinib, afatinib or osimertinib represent the first-line treatment of choice. However, patients eventually develop resistance

Fibrosis occurs when chronic inflammation or persistent injury leads to the development of excessive connective tissue, which can lead to organ damage and impaired function. Fibrotic diseases can

As per terms of the deal, Novartis will purchase all outstanding shares of Endocyte common stock by paying $24 per share. Through using drug conjugation technology, Endocyte will

Earlier this month, the company said that Chronocort could not confirm its superiority over conventional treatment in endocrine control over a 24-hour period, which was the primary objective

There are an estimated 33 million patients with dry eye disease in the U.S. and Kala’s market research indicates that approximately 90% of these patients have flares associated

Revolution Medicines and Warp Drive Bio are biotechnology firms involved in the studying of molecules and mechanisms of nature to discover first or best-in-class drugs. The deal will

Lynparza has been designed to exploit DNA damage response (DDR) pathway deficiencies, like the BRCA mutations, to preferentially eliminate cancer cells. Especially, in vitro studies have demonstrated that